arrow_back Back Filing freshness 20-F Q4 FY2025 SEC EDGAR

download Export Data

Chemomab Therapeutics Ltd.

CMMB

$1.87 ▲ +0.10 (+5.65%) at close

22 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Chemomab Therapeutics Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC —

FCF / Share None

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

22-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-8.75M

↓ -71.5% —

FCF / Share Free cash flow per share

$-0.03

↓ -40.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q4 FY2025 Dec 31, 2025 20-F ↗	Q4 FY2024 Dec 31, 2024 20-F ↗	Q4 FY2023 Dec 31, 2023 20-F ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 20-F ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 20-F ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2018 Dec 31, 2018 10-K ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
EPS Growth YoY (%)	—	—	—	—	63.6% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	169.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	107.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	—	—	—	-71.5% Weak ↑ Weak Improving Year-over-year change in net income	-64.3% Weak ↑ Weak Improving Year-over-year change in net income	-199.5% Weak ↓ Weak Declining Year-over-year change in net income	-199.5% Weak ↓ Weak Declining Year-over-year change in net income	-199.5% Weak ↓ Weak Declining Year-over-year change in net income	-158.1% Weak ↓ Weak Declining Year-over-year change in net income	30.4% Excellent ↓ Excellent Declining Year-over-year change in net income	51.8% Excellent ↓ Excellent Declining Year-over-year change in net income	51.8% Excellent ↓ Excellent Declining Year-over-year change in net income	65.2% Excellent → Excellent Stable Year-over-year change in net income	65.8% Excellent → Excellent Stable Year-over-year change in net income	64.3% Excellent Excellent Year-over-year change in net income	64.3% Excellent Excellent Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	—	—	—	—	—	-104.6% Weak Weak Year-over-year change in free cash flow	5.2% Fair Fair Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q4 FY2025 Dec 31, 2025 20-F ↗	Q4 FY2024 Dec 31, 2024 20-F ↗	Q4 FY2023 Dec 31, 2023 20-F ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 20-F ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 20-F ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2018 Dec 31, 2018 10-K ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	8.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	—	—	—	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.12x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.51x Excellent ↓ Excellent Declining Free cash flow relative to reported net income Optimal: > 1x	3.35x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.52x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.32x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 1 metrics

Metric	Q4 FY2025 Dec 31, 2025 20-F ↗	Q4 FY2024 Dec 31, 2024 20-F ↗	Q4 FY2023 Dec 31, 2023 20-F ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 20-F ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 20-F ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2018 Dec 31, 2018 10-K ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Return on Common Equity (%) (%)	—	—	—	-31.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-309%)	-22.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-252%)	-11.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-176%)	-9.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-166%)	-8.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-159%)	-8.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-155%)	-2.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-117%)	-2.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-117%)	-3.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-121%)	-18.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-220%)	-45.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-405%)	-43.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-389%)	-30.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-304%)	-37.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-351%)	-35.1% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-334%)	-36.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-342%)	-31.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-311%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q4 FY2025 Dec 31, 2025 20-F ↗	Q4 FY2024 Dec 31, 2024 20-F ↗	Q4 FY2023 Dec 31, 2023 20-F ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 20-F ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 20-F ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2018 Dec 31, 2018 10-K ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Net Debt (USD)	$-7.56M	$-6.07M	$-9.29M	$-20.77M	—	$-10.74M	$-9.88M	$-13.83M	—	—	—	$-58.18M	$-11.67M	$-6.77M	$-8.82M	$-14.01M	$-17.57M	$-23.24M	$-27.00M	$-32.13M	$-7.52M	—

📊 What does each share earn? 5 metrics

Metric	Q4 FY2025 Dec 31, 2025 20-F ↗	Q4 FY2024 Dec 31, 2024 20-F ↗	Q4 FY2023 Dec 31, 2023 20-F ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 20-F ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 20-F ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2018 Dec 31, 2018 10-K ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Basic EPS, GAAP (USD)	—	—	—	$0.04	$0.04	$0.04	$0.03	—	$0.02	$0.01	$0.01	—	—	—	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	—	—	—	$-0.03	—	$-0.02	$-0.03	—	—	$-0.01	$-0.03	—	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	—	—	—	$0.12	—	$0.19	$0.23	$0.25	—	$0.29	$0.31	$0.26	—	$0.90	$1.37	$1.95	$2.51	—	—	—	$3.93	—
Tangible Book Value per Share (USD)	—	—	—	$0.12	—	$0.19	$0.23	$0.25	—	$0.29	$0.31	$0.26	—	$0.90	$1.37	$1.95	$2.51	—	—	—	$3.93	—
Basic Weighted Avg Shares (shares)	—	—	—	221.00M	—	228.77M	228.17M	—	—	227.96M	216.27M	—	—	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q4 FY2025 Dec 31, 2025 20-F ↗	Q4 FY2024 Dec 31, 2024 20-F ↗	Q4 FY2023 Dec 31, 2023 20-F ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 20-F ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 20-F ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2018 Dec 31, 2018 10-K ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$11.95M	$12.82M	$16.06M	$26.78M	—	$43.25M	$50.44M	$55.82M	—	—	—	$54.89M	$10.52M	$5.11M	$7.92M	$11.21M	$14.09M	—	—	—	$8.17M	—
Total Equity (USD)	$12.33M	$13.54M	$17.00M	$27.95M	$36.22M	$44.62M	$51.84M	$57.24M	$61.47M	$65.51M	$68.04M	$55.16M	$10.80M	$5.35M	$8.16M	$11.56M	$14.91M	$20.40M	$27.27M	$31.34M	$9.80M	$-609.00K

📋 What is driving earnings? 3 metrics

Metric	Q4 FY2025 Dec 31, 2025 20-F ↗	Q4 FY2024 Dec 31, 2024 20-F ↗	Q4 FY2023 Dec 31, 2023 20-F ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 20-F ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 20-F ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2018 Dec 31, 2018 10-K ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Depreciation Expense (USD)	—	—	—	$16.00K	$14.00K	$17.00K	$14.00K	$13.00K	$11.00K	$9.00K	$7.00K	$7.00K	$6.00K	—	—	$71.00K	$211.00K	$28.00K	$21.00K	$21.00K	—	—
Net Income, GAAP (USD)	—	—	—	$-8.75M	$-8.27M	$-5.10M	$-5.10M	$-5.10M	$-5.04M	$-1.70M	$-1.70M	$-1.70M	$-1.95M	$-2.45M	$-3.54M	$-3.54M	$-5.60M	$-7.17M	$-9.91M	$-9.91M	—	—
Operating Cash Flow (USD)	—	—	—	$-7.19M	$-5.70M	$-5.25M	$-5.70M	$-3.71M	$-2.89M	$-2.58M	$-5.61M	$-1.29M	$-1.55M	—	—	$-3.54M	$-5.91M	$-3.51M	$-3.92M	$-3.12M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 22 quarters

Chemomab Therapeutics Ltd.

Analytical Summary

22-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CMMB with peers